NeuroVive Pharmaceutical AB Year End Report January - December 2019

Important events in 2019





Strategy and communications


Important events after the reporting period

Financial information fourth quarter (Oct-Dec 2019)*

Financial information full year 2019 (Jan-Dec 2019)*

* APM Alternative perfomance measures, see definition on page 17 in the Report.

The complete Year End report is available for download below and through NeuroVive's web site

The information was submitted for publication, through the agency of the contact person set out below at 08:40 a.m. CET on 19 February 2020.

For more information please contact:
Erik Kinnman, CEO
+46 (0)46 275 62 20

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard),
For news subscription, please visit  

About NeuroVive 
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury (TBI) is ready to enter a clinical phase II efficacy study. The R&D portfolio also consists of early projects for primary mitochondrial disease, and NASH. NeuroVive’s ambition is to take drugs for primary mitochondrial diseases through clinical development and all the way to market, with or without partners. For the TBI and NASH projects the goal is to enter strategic partnerships. A subset of compounds under NeuroVive’s NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTC Market’s Pink Open market in the US (OTC: NEVPF).